One patent currently held, every record listed here
8 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Aug 2034. from the record
Of the 8 now held by other companies, 3 name Lonza Bend Inc. as their current owner, and 5 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Aug 2034
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2010 to 2034.
US 9,545,384
Nanoparticles Comprising Drug, a Non-Ionizable Cellulosic Polymer and Tocopheryl Polyethylene Glocol Succinate
Oct 29, 2032
20152020202520302034
Every computed term in this portfolio is shown above.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends Apr 2028 · Medium confidence
The largest patent family in this portfolio, 5 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2028.
now held by Pfizer, Inc.
Also notable
Ends Feb 2028 · Medium confidence
Granted 2015 and renewed at every maintenance window due so far. Protection runs to 2028.
now held by Lonza Bend Inc.
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| ANTI-CTLA-4 Antibody Compositions | 1 in force | to Aug 2034 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,487,581 | ANTI-CTLA-4 Antibody Compositions held by Pfizer Inc. and Pfizer Products Inc. In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 8 patents in force now held by others · 175 patents ended · 142 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 patents carry no fee events. That is a gap in the record, not evidence of lapse, so status falls back to the computed term
13 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed